Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.56 |
| ▸ | HTR1A | P08908 | 6/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.48 |
| ▸ | DRD4 | P21917 | 4/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.48 |
| ▸ | HTR7 | P34969 | 2/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4424774 | 0.82 | OPRM1 (0.56) | OPRM1HTR1AADRA1ADRD4ADRA1B | |
| SCHEMBL8136249 | 0.82 | HTR1A (0.65) | HTR1AADRA1ADRD4ADRA1BHTR7 | |
| SCHEMBL13533329 | 0.80 | OPRM1 (0.55) | OPRM1HTR1AADRA1ADRD4ADRA1B | |
| SCHEMBL13533328 | 0.80 | OPRM1 (0.55) | OPRM1HTR1AADRA1ADRD4ADRA1B | |
| SCHEMBL8001428 | 0.79 | HTR1A (0.73) | OPRM1HTR1AADRA1ADRD4ADRA1B | |
| SCHEMBL9051902 | 0.79 | HTR1A (0.73) | OPRM1HTR1AADRA1ADRD4ADRA1B | |
| SCHEMBL8011497 | 0.79 | HTR1A (0.73) | OPRM1HTR1AADRA1ADRD4ADRA1B | |
| SCHEMBL13085826 | 0.76 | HTR1A (0.72) | OPRM1HTR1AADRA1ADRD4ADRA1B | |
| SCHEMBL13085827 | 0.76 | HTR1A (0.72) | OPRM1HTR1AADRA1ADRD4ADRA1B | |
| SCHEMBL8543106 | 0.75 | OPRM1 (0.62) | OPRM1HTR1AADRA1ADRD4ADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2026783-A2 | METHOD FOR ENHANCING COGNITIVE FUNCTION | Wyeth a Corporation of the State of Delaware (US) | 2009-02-25 | — | — | EP | claimed |
| US-20080032965-A1 | Method for enhancing cognitive function | WYETH | 2008-02-07 | — | — | US | claimed |
| WO-2007146073-A2 | METHOD FOR ENHANCING COGNITIVE FUNCTION | WYETH (US) | 2007-12-21 | — | — | WO | claimed |
| US-20060287335-A1 | Serotonergic agents for treating sexual dysfunction | WYETH (US) | 2006-12-21 | — | — | US | claimed |
| EP-1534258-A2 | AGONISM OF THE 5HT 2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION | Wyeth (US) | 2005-06-01 | — | — | EP | claimed |
| US-20040063721-A1 | Agonism of the 5HT2A receptor for treatment of thermoregulatory dysfunction | WYETH | 2004-04-01 | — | — | US | claimed |
| WO-2004016256-A2 | AGONISM OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION | WYETH (US) | 2004-02-26 | — | — | WO | claimed |
| EP-0763031-B1 | PIPERAZINE DERIVATIVES AS 5HT1A ANTAGONISTS | WYETH JOHN & BROTHER LTD (GB) | 2000-05-10 | — | — | EP | claimed |
| EP-0763031-A1 | PIPERAZINE DERIVATIVES AS 5HT1A ANTAGONISTS | JOHN WYETH & BROTHER LIMITED (GB) | 1997-03-19 | — | — | EP | claimed |
| WO-1995033743-A1 | PIPERAZINE DERIVATIVES AS 5HT1A ANTAGONISTS | JOHN WYETH & BROTHER LIMITED (GB) | 1995-12-14 | — | — | WO | claimed |
| EP-1971337-A1 | SEROTONERGIC AGENTS FOR TREATING SEXUAL DYSFUNCTION | Wyeth a Corporation of the State of Delaware (US) | 2008-09-24 | — | — | EP | disclosed |
| US-7425558-B2 | -4-substituted-N-(2-(4-(2,3-dihydro-benzo(1,4)dioxin-5-yl)-piperazin -1-yl)propy l)-N-pyridin-2-yl-benzamide or salts; 5-HT1A receptor antagonists; urinary incontinence | WYETH (US) | 2008-09-16 | — | — | US | disclosed |
| US-20080070925-A1 | SEROTONERGIC AGENTS FOR TREATING SEXUAL DYSFUNCTION | WYETH LLC | 2008-03-20 | — | — | US | disclosed |
| US-20080032965-A1 | Method for enhancing cognitive function | WYETH | 2008-02-07 | — | — | US | disclosed |
| WO-2007081374-A1 | SEROTONERGIC AGENTS FOR TREATING SEXUAL DYSFUNCTION | WYETH (US) | 2007-07-19 | — | — | WO | disclosed |
| EP-1534258-A2 | AGONISM OF THE 5HT 2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION | Wyeth (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040063721-A1 | Agonism of the 5HT2A receptor for treatment of thermoregulatory dysfunction | WYETH | 2004-04-01 | — | — | US | disclosed |
| WO-2004016256-A2 | AGONISM OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION | WYETH (US) | 2004-02-26 | — | — | WO | disclosed |
| EP-0763031-B1 | PIPERAZINE DERIVATIVES AS 5HT1A ANTAGONISTS | WYETH JOHN & BROTHER LTD (GB) | 2000-05-10 | — | — | EP | disclosed |
| US-5723464-A | CENTRAL NERVOUS SYSTEM DISORDERS, ANXIETY OR DEPRESSION | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287335-A1 | Serotonergic agents for treating sexual dysfunction | HTR5A, HTR1A, HTR3A | OPRM1 140/4885HTR1A 2/4885ADRA1A 30/4885 |
| US-20080032965-A1 | Method for enhancing cognitive function | HTR2A, HTR5A, HTR1A | OPRM1 149/4885HTR1A 3/4885ADRA1A 62/4885 |
| US-20080070925-A1 | SEROTONERGIC AGENTS FOR TREATING SEXUAL DYSFUNCTION | HTR5A, HTR1A, HTR3A | OPRM1 140/4885HTR1A 2/4885ADRA1A 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.